Literature DB >> 16061883

Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma.

Vincenzo Damiano1, Davide Melisi, Cataldo Bianco, David Raben, Rosa Caputo, Gabriella Fontanini, Roberto Bianco, Anderson Ryan, A Raffaele Bianco, Sabino De Placido, Fortunato Ciardiello, Giampaolo Tortora.   

Abstract

PURPOSE: Glioblastoma multiforme is an aggressive disease in which vascular endothelial growth factor (VEGF) and the EGF receptor (EGFR) are implicated in tumor growth, relapse, and resistance to radiotherapy and chemotherapy. The VEGF receptors VEGFR-1 (flt-1) and VEGFR-2 (KDR), typically present on endothelial cells, have also been identified in human glioblastoma tissues and cell lines. In addition, EGFR is dysregulated in the majority of human glioblastomas and EGFR overexpression correlates with shorter survival. We have investigated the antitumor and antiangiogenic effect of ZD6474, an inhibitor of both VEGFR and EGFR signaling as a single agent and in combination with ionizing radiation. EXPERIMENTAL
DESIGN: We have used ZD6474 and/or ionizing radiation in human glioblastoma cell lines D54 and U251 in vitro and in nude mice bearing established xenografts. The effects of treatment on tumor blood vessels and protein expression were evaluated by Western blot and immunohistochemistry.
RESULTS: As single agents, ionizing radiation and ZD6474 caused a dose-dependent inhibition of soft agar growth in D54 and U251 cell lines, whereas a cooperative effect was obtained in combination. Treatment of mice bearing D54 xenografts with either ZD6474 or radiotherapy alone caused tumor growth inhibition that was reversible upon treatment cessation. A cooperative and long-lasting inhibition of tumor growth was obtained with ZD6474 in combination with concomitant radiotherapy. The antiproliferative effect was accompanied by inhibition of VEGF protein expression and inhibition of angiogenesis as measured by vessel counting.
CONCLUSION: This study shows the antitumor activity of ZD6474 in combination with ionizing radiation in glioblastoma both in vitro and in vivo, and provides a scientific rationale to evaluate ZD6474 alone or in combination with radiotherapy in patients affected by this disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16061883     DOI: 10.1158/1078-0432.CCR-05-0174

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  26 in total

Review 1.  Applications of molecular imaging.

Authors:  Craig J Galbán; Stefanie Galbán; Marcian E Van Dort; Gary D Luker; Mahaveer S Bhojani; Alnawaz Rehemtulla; Brian D Ross
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

Review 2.  Experimental approaches for the treatment of malignant gliomas.

Authors:  Leopold Arko; Igor Katsyv; Grace E Park; William Patrick Luan; John K Park
Journal:  Pharmacol Ther       Date:  2010-06-08       Impact factor: 12.310

Review 3.  Understanding the role of tumor stem cells in glioblastoma multiforme: a review article.

Authors:  Aalya Fatoo; Michael J Nanaszko; Baxter B Allen; Christina L Mok; Elena N Bukanova; Robel Beyene; Jennifer A Moliterno; John A Boockvar
Journal:  J Neurooncol       Date:  2010-09-18       Impact factor: 4.130

Review 4.  A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.

Authors:  David A Reardon; Scott Turner; Katherine B Peters; Annick Desjardins; Sridharan Gururangan; John H Sampson; Roger E McLendon; James E Herndon; Lee W Jones; John P Kirkpatrick; Allan H Friedman; James J Vredenburgh; Darell D Bigner; Henry S Friedman
Journal:  J Natl Compr Canc Netw       Date:  2011-04       Impact factor: 11.908

5.  Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab.

Authors:  Jidong Hong; Yuping Peng; Yuping Liao; Wuzhong Jiang; Rui Wei; Lei Huo; Zaide Han; Chaojun Duan; Meizuo Zhong
Journal:  Exp Ther Med       Date:  2012-04-19       Impact factor: 2.447

6.  Progress on antiangiogenic therapy for patients with malignant glioma.

Authors:  Manmeet S Ahluwalia; Candece L Gladson
Journal:  J Oncol       Date:  2010-04-06       Impact factor: 4.375

7.  Knockdown of vascular endothelial cell growth factor expression sensitizes U251 glioma cells to liposomal paclitaxel and radiation treatment in vitro.

Authors:  Yang Yu; Jianguo Feng; Xiangyun Zong; Hongjian Yang; Dehong Zou; Xiangming He
Journal:  Exp Ther Med       Date:  2011-11-11       Impact factor: 2.447

Review 8.  Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis.

Authors:  Christine E Eyler; Jeremy N Rich
Journal:  J Clin Oncol       Date:  2008-06-10       Impact factor: 44.544

9.  Dual targeting of IGF-1R and PDGFR inhibits proliferation in high-grade gliomas cells and induces radiosensitivity in JNK-1 expressing cells.

Authors:  Mia Carapancea; Daria Cosaceanu; Raluca Budiu; Anna Kwiecinska; Ligia Tataranu; Vasile Ciubotaru; Oana Alexandru; Monica Banita; Catalina Pisoschi; Magnus L Bäcklund; Rolf Lewensohn; Anica Dricu
Journal:  J Neurooncol       Date:  2007-06-14       Impact factor: 4.130

Review 10.  Radiosensitizers in the temozolomide era for newly diagnosed glioblastoma.

Authors:  Peter Mathen; Lindsay Rowe; Megan Mackey; DeeDee Smart; Philip Tofilon; Kevin Camphausen
Journal:  Neurooncol Pract       Date:  2019-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.